Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

4-1BB (CD137, TNFRSF9) mediates costimulatory signals important for activation and persistence of cytotoxic T lymphocytes. In this issue of JEM, Oda et al. (https://doi.org/10.1084/jem.20191166) report on a chimeric construction encompassing extracellular Fas and intracellular 4-1BB to dramatically improve adoptive T cell therapy.

Original publication

DOI

10.1084/jem.20201562

Type

Journal article

Journal

The Journal of experimental medicine

Publication Date

12/2020

Volume

217

Addresses

Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.

Keywords

T-Lymphocytes, Cytotoxic, Chimera, Immunotherapy, Adoptive, Cell- and Tissue-Based Therapy, Tumor Necrosis Factor Receptor Superfamily, Member 9